These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11866009)

  • 1. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis.
    App EM; Baran D; Dab I; Malfroot A; Coffiner M; Vanderbist F; King M
    Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
    Dasgupta B; King M
    Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
    Sun F; Tai S; Lim T; Baumann U; King M
    Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients.
    Vanderbist F; Wery B; Baran D; Van Gansbeke B; Schoutens A; Moës AJ
    Drug Dev Ind Pharm; 2001; 27(3):205-12. PubMed ID: 11291200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog.
    Tomkiewicz RP; App EM; De Sanctis GT; Coffiner M; Maes P; Rubin BK; King M
    Pulm Pharmacol; 1995 Dec; 8(6):259-65. PubMed ID: 8819180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
    Noone PG; Hamblett N; Accurso F; Aitken ML; Boyle M; Dovey M; Gibson R; Johnson C; Kellerman D; Konstan MW; Milgram L; Mundahl J; Retsch-Bogort G; Rodman D; Williams-Warren J; Wilmott RW; Zeitlin P; Ramsey B;
    Pediatr Pulmonol; 2001 Aug; 32(2):122-8. PubMed ID: 11477729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).
    Dietzsch HJ; Gottschalk B; Heyne K; Leupoid W; Wunderlich P
    Pediatrics; 1975 Jan; 55(1):96-100. PubMed ID: 1110869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucolytic treatment with N-acetylcysteine L-lysinate metered dose inhaler in dogs: airway epithelial function changes.
    Tomkiewicz RP; App EM; Coffiner M; Fossion J; Maes P; King M
    Eur Respir J; 1994 Jan; 7(1):81-7. PubMed ID: 8143836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
    Feng W; Garrett H; Speert DP; King M
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis.
    Hofmann T; Senier I; Bittner P; Hüls G; Schwandt HJ; Lindemann H
    J Aerosol Med; 1997; 10(2):147-58. PubMed ID: 10168532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage.
    App EM; Kieselmann R; Reinhardt D; Lindemann H; Dasgupta B; King M; Brand P
    Chest; 1998 Jul; 114(1):171-7. PubMed ID: 9674466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
    Nash EF; Stephenson A; Ratjen F; Tullis E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007168. PubMed ID: 19160327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate.
    Stigliani M; Manniello MD; Zegarra-Moran O; Galietta L; Minicucci L; Casciaro R; Garofalo E; Incarnato L; Aquino RP; Del Gaudio P; Russo P
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):337-45. PubMed ID: 26741302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis.
    Gomez CCS; Parazzi PLF; Clinckspoor KJ; Mauch RM; Pessine FBT; Levy CE; Peixoto AO; Ribeiro MÂGO; Ribeiro AF; Conrad D; Quinton PM; Marson FAL; Ribeiro JD
    Clin Drug Investig; 2020 Feb; 40(2):105-117. PubMed ID: 31721070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
    Deterding R; Retsch-Bogart G; Milgram L; Gibson R; Daines C; Zeitlin PL; Milla C; Marshall B; Lavange L; Engels J; Mathews D; Gorden J; Schaberg A; Williams J; Ramsey B;
    Pediatr Pulmonol; 2005 Apr; 39(4):339-48. PubMed ID: 15704203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
    Homnick DN; Marks JH; Rubin BK
    J Aerosol Med; 2007; 20(1):45-9. PubMed ID: 17388752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
    Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.